Skip to content
TrialScanner

NCT05619783

Extension Study Evaluating The Safety And Tolerability of AMX0035

Phase 3CompletedAMLXLead

Registry record

Lead sponsor
Amylyx Pharmaceuticals Inc.
Conditions
Amyotrophic Lateral Sclerosis
Primary completion
Oct 16, 2024Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT05619783 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT05619783: Extension Study Evaluating... | TrialScanner